Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer

NCT01436214 is registered in ClinicalTrials.gov with Adamis Pharmaceuticals Corporation as lead sponsor.

NCT NCT01436214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01436214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer
Lead sponsor
Adamis Pharmaceuticals Corporation
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 31, 2011
Completion date
August 31, 2017
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer